Trade Names:Ontak- Injection, solution, concentrate 150 mcg/mL
Denileukin, a recombinant DNA-derived cytotoxic protein fused to diphtheria toxin fragments A and B, is designed to direct the cytocidal action of diphtheria toxin to cells that express the IL-2 receptor.
Distribution half-life approximately 2 to 5 min. Vd is 0.06 to 0.09 L/kg.
Metabolized by proteolytic degradation.
Terminal half-life approximately 70 to 80 min. Cl approximately 0.6 to 2 mL/min/kg.
Treatment of persistent or recurrent cutaneous T-cell lymphoma whose malignant cells express the CD25 component of the IL-2 receptor.
Treatment of chronic lymphocytic leukemia refractory to fludarabine; non-Hodgkin lymphoma.
IV 1 treatment cycle is 9 or 18 mcg/kg/day administered for 5 consecutive days every 21 days for 8 cycles. Infuse over 30 to 60 min.Dosage Adjustments Adults
Delay therapy in patients with serum albumin below 3 g/dL.
Store frozen at no more than −10°C (14°F). Must be brought to room temperature, at no more than 25°C (77°F), before preparing the dose. The vials may be thawed in the refrigerator at 2° to 8°C (36° to 46°F) for no more than 24 h or at room temperature for 1 to 2 h. Do not heat denileukin. Do not refreeze.
None well documented.
None well documented.
Hypotension (16%); capillary leak syndrome (11%).
Pyrexia (64%); fatigue (47%); headache (29%); asthenia (18%); dizziness (13%).
Rash (24%); pruritus (18%).
Visual changes, including acuity (4%).
Nausea (60%); vomiting (35%); diarrhea (22%); anorexia (20%); dysgeusia (11%).
Increased ALT or AST (84%).
Evidence of denileukin neutralizing antibodies approached 100% after 3 courses of treatment.
Rigors (47%); myalgia (20%); back pain (18%); arthralgia (16%).
Cough (20%); dyspnea, upper respiratory tract infection (13%).
Peripheral edema (26%); chest pain, pain (13%); infusion reactions (8%).
Serious and fatal infusion reactions have been reported. Administer in a facility equipped and staffed for cardiopulmonary resuscitation. If serious infusion reactions occur, immediately stop and permanently discontinue denileukin.Capillary leak syndrome
Capillary leak syndrome resulting in death has been reported. Monitor weight, edema, BP, and serum albumin levels prior to and during treatment.Visual acuity
Loss of visual acuity and color vision have been reported.
Prior to administration of this product, test the patient's malignant cells for CD25 expression. Perform a CBC and a blood chemistry panel, including liver and renal function and serum albumin levels, prior to initiation of treatment and weekly during therapy. Monitor weight, edema, and BP prior to and during treatment.
Category C .
Undetermined. Patients receiving denileukin should discontinue breast-feeding.
Safety and efficacy not established.
Clinical studies did not include sufficient numbers of subjects 65 yr of age and older to determine whether they respond differently from younger subjects.
Occurs within 2 wk after starting therapy. Take special caution in patients with preexisting CV disease.
Chills, fever, moderate to severe nausea, persistent asthenia, vomiting.
Copyright © 2009 Wolters Kluwer Health.